5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, M S Aapro, F André, C H Barrios, J Bergh, G S Bhattacharyya, L Biganzoli, F Boyle, M-J Cardoso, L A Carey, J Cortés, N S El Saghir, M Elzayat, A Eniu, L Fallowfield, P A Francis, K Gelmon, J Gligorov, R Haidinger, N Harbeck, X Hu, B Kaufman, R Kaur, B E Kiely, S-B Kim, N U Lin, S A Mertz, S Neciosup, B V Offersen, S Ohno, O Pagani, A Prat, F Penault-Llorca, H S Rugo, G W Sledge, C Thomssen, D A Vorobiof, T Wiseman, B Xu, L Norton, A Costa, E P Winer, F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, M S Aapro, F André, C H Barrios, J Bergh, G S Bhattacharyya, L Biganzoli, F Boyle, M-J Cardoso, L A Carey, J Cortés, N S El Saghir, M Elzayat, A Eniu, L Fallowfield, P A Francis, K Gelmon, J Gligorov, R Haidinger, N Harbeck, X Hu, B Kaufman, R Kaur, B E Kiely, S-B Kim, N U Lin, S A Mertz, S Neciosup, B V Offersen, S Ohno, O Pagani, A Prat, F Penault-Llorca, H S Rugo, G W Sledge, C Thomssen, D A Vorobiof, T Wiseman, B Xu, L Norton, A Costa, E P Winer

No abstract available

Keywords: ABC; ESO-ESMO; advanced; breast cancer; guidelines; metastatic.

Conflict of interest statement

Disclosure MSA reports receipt of consultation fees from Amgen, BMS, Celgene, Clinigen, Eisai, Genomic Health, GSK, Helsinn, Hospira, JnJ, Novartis, Merck, Merck Serono, Mundipharma, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro, Tevam Vifor, G1 Therapeutics and Lilly; receipt of honoraria for symposia lectures from Amgen, Bayer, Schering, Cephalon, Chugai, Eisai, Genomic Health, GSK, Helsinn, Hospira, Ipsen, JnJ Ortho Biotech, Kyowa Hakko Kirin, Merck, Merck Serono, Mundipharma, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Tesaro, Taiho, Tevam Vifor, G1 Therapeutics and Lilly. CHB reports receipt of honoraria or consultation fees from Boehringer Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, MSD, AstraZeneca and Bayer; receipt of grants/research support to the institution from AbbVie, Amgen, Astellas Pharma, AstraZeneca, BMS, Celgene, Covance, Lilly, Medivation, Merck Serono, MSD, Novartis, Pfizer, PharmaMar and Roche/Genentech. JB reports receipt of grants/research support grants to Karolinska Institute and University Hospital from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche, Sanofi-Aventis; no personal payments; payment from UpToDate to Asklepios Medicine HB for a chapter on breast cancer prediction. LB reports receipt of grants/research support from Celgene, Genomic Health and Novartis; receipt of honoraria or consultation fees from AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pfizer, Pierre Fabre and Roche. FC reports receipt of honoraria or consultation fees from Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, GE Oncology, Genentech, GSK, MacroGenics, Medscape, MSD, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre Fabre, prIME Oncology, Roche, Sanofi, Seattle Genetics and Teva. JC reports acting as a consultant/advisor for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, MSD, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim and Kyowa Kirin; received honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, MSD and Daiichi Sankyo; received research funding to the institution from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, MSD, Pfizer, PIQUR Therapeutics, Puma C and Queen Mary University of London; holds stock, patents and intellectual property for MEDSIR; received travel, accommodation and expenses from Roche, Novartis, Eisai, Pfizer and Daiichi Sankyo. GC reports receipt of honoraria or consultation fees from Roche, Pfizer, Lilly, Novartis and SeaGen; participation in a sponsored speakers' bureau for SeaGen, Pfizer, Lilly and Novartis. NSES reports receipt of grants/research support to institution from Novartis; receipt of honoraria or consultation fees from Novartis, Roche, Pfizer, Lilly and AstraZeneca. ME reports acting in an advisory role for Novartis and Roche. AE reports receipt of grants/research support from AstraZeneca, Roche, Celltrion, Pfizer and Novartis. LF reports receipt of grants/research support from BMS, GSK, Myriad and Novartis; receipt of honoraria or consultation fees from BMS, AstraZeneca, Teva, Novartis, Eisai, Takeda, Pfizer, Lilly, Genomic Health and Myriad. PAF reports receipt of honoraria or consultation fees from AstraZeneca and Novartis; travel for lecture for Pfizer and Ipsen. KG reports receipt of grants/research support from AstraZeneca, Pfizer and BMS; receipt of honoraria or consultation fees from Pfizer, AstraZeneca, Novartis, Nanostring, Merck, Mylan, Genomic Health, Roche and BMS. JG reports receipt of grants/research support from Amgen, Eisai, Genomic Health, Novartis, Pfizer and Roche/Genentech; receipt of honoraria or consultation fees from Daiichi, Eisai, Genomic Health, Ipsen, MacroGenics, MSD, Mylan, Novartis, Onxeo, Pfizer and Roche/Genentech; participation in a sponsored speakers' bureau for Eisai, Genomic Health, Ipsen, Novartis, Pfizer and Roche/Genentech. NH reports receipt of honoraria or consultation fees from Amgen, AstraZeneca, Celgene, Daiichi Sakyo, Lilly, MSD, Novartis, Odonate, Pfizer, Roche, Sandoz/Hexal and Seattle Genetics. RK reports receipt of grants/research support from Pfizer Malaysia. BEK reports receipt of grants/research support to institution from Roche; receipt of honoraria for advisory boards and educational presentations as well as travel and meeting expenses from Roche; receipt of honoraria for advisory boards and educational presentations from Novartis. SBK reports receipt of grants/research support to institution from Novartis, Sanofi-Aventis, Kyowa Kirin Inc. and DongKook Pharm Co.; receipt of consultancy fees from Novartis, AstraZeneca, Lilly, Enzychem, Daehwa Pharmaceutical Co. Ltd, ISU ABXIS and Daiichi Sankyo. NUL reports receipt of grants/research support from Genentech and Seattle Genetics; receipt of honoraria or consultation fees from Seattle Genetics, Daiichi Sankyo and Puma. SAM reports receipt of honoraria from Pfizer and Lilly; SN reports receipt of grants/research support from Roche, Pfizer, BMS and Novartis; participation in a sponsored speakers' bureau for Roche, Pfizer, BMS, Merck and Novartis. LN reports receipt of honoraria from Sermonix Oncology Ad Board, Prime Oncology, Sarah Lawrence Lecture, Context advisory board, Oncology Pioneers Science Lecture Series, BCRF programmatic review meeting and CSHL external advisory board meeting. SO reports receipt of grants/research support from Chugai, Eisai, Taiho, Daiichi Sankyo; participation in a sponsored speakers' bureau for Chugai, AstraZeneca, Eisai, Taiho, Pfizer and Lilly. OP reports participation in a sponsored speakers' bureau for Takeda, Roche, Pfizer, Novartis and Lilly. SPS has participated in a speakers' bureau and received honoraria from Roche, AstraZeneca, Novartis, Pfizer, Nanostring and Teva; reports consultancy for Roche, AstraZeneca, Novartis and Pfizer. FPL reports receipt of grants/research support from Roche; receipt of honoraria or consultation fees from Roche, Puma, Pierre Fabre and AstraZeneca. AP reports personal financial interests and lecture fees for Roche, Pfizer, Novartis, Amgen, BMS and Daiichi Sankyo; participation in an advisory role/consultancy for Roche, Pfizer, Novartis, Amgen, BMS, Puma and Oncolytics Biotech; institutional financial interests include contracted research for Novartis, Nanostring, Roche and Boehringer; lecture fees from Nanostring technologies; clinical trials for Novartis, Roche, Boehringer, Daiichi Sankyo, Pfizer, Lilly and Amgen. HSR reports receipt of grants/research support from Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi Sankyo, Eisai, Seattle Genetics, MacroGenics and Immunomedics. ES reports receipt of honoraria or consultation fees from Amgen, AstraZeneca, Clinigen, Egis, Eli Lilly, Genomic Health, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz and TLC Biopharmaceuticals; travel support from Amgen, AstraZeneca, Egis, Novartis, Pfizer and Roche; contracted research for Amgen, AstraZeneca, Boehringer, Eli Lilly, Merck, Novartis, Pfizer, Roche and Samsung; holds stock in Eli Lilly. EPW reports receipt of grants/research support from Merck and Genentech/Roche; receipt of honoraria or consultation fees from Carrick Therapeutics, Genentech/Roche, Genomic Health, GSK, Jounce, Leap, Lilly, Merck and Seattle Genetics; research fees to institute from Genentech/Roche and Merck; participation in a scientific advisory board for Leap. BX reports receipt of advisory fees from Novartis and Roche; fees for serving on a speakers' bureau from AstraZeneca, Pfizer, Roche and Eisai. FA, FB, BK, FEL, GWS, CT and TW have not reported any potential conflict of interest. GSB, MJC, LAC, AC, RH, XH, BVO and DAV have declared no significant conflict of interest.

References

    1. Cardoso F., Costa A., Norton L., et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Breast. 2014;23(5):489–502.
    1. Cardoso F., Costa A., Norton L., et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Ann Oncol. 2014;25(10):1871–1888.
    1. Cardoso F., Spence D., Mertz S., et al. Global analysis of advanced/metastatic breast cancer: decade report (2005-2015) Breast. 2018;39:131–138.
    1. Howlader N., Noone A.M., Krapcho M., et al., editors. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Based on November 2015 SEER Data Submission. SEER; Bethesda, MD: 2016. Available at.
    1. Sundquist M., Brudin L., Tejler G. Improved survival in metastatic breast cancer 1985-2016. Breast. 2017;31:46–50.
    1. Kobayashi K., Ito Y., Matsuura M., et al. Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today. 2016;46(7):821–826.
    1. Fietz T., Tesch H., Rauh J., et al. Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer—results from the prospective German TMK cohort study. Breast. 2017;34:122–130.
    1. Gobbini E., Ezzalfani M., Dieras V., et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer. 2018;96:17–24.
    1. Deluche E., Antoine A., Bachelot T., et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. Eur J Cancer. 2020;129:60–70.
    1. Malmgren J.A., Mayer M., Atwood M.K., et al. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010. Breast Cancer Res Treat. 2018;167(2):579–590.
    1. Breast Cancer Foundation NZ “I'm still here”. Insights into living—and dying–with advanced breast cancer in New Zealand. Breast Cancer Foundation NZ. Available at.
    1. Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
    1. Cherny N.I., Dafni U., Bogaerts J., et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28(10):2340–2366.
    1. Dykewicz C.A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139–144. (adapted from: Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis. 1994;1918:1421)
    1. Mack J.W., Weeks J.C., Wright A.A., et al. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol. 2010;28(7):1203–1208.
    1. Smith-Uffen M.E.S., Johnson S.B., Martin A.J., et al. Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients. Support Care Cancer. 2020;28(7):3399–3407.
    1. Hagerty R.G., Butow P.N., Ellis P.M., et al. Communicating prognosis in cancer care: a systematic review of the literature. Ann Oncol. 2005;16(7):1005–1053.
    1. Fried T.R., Bradley E.H., O'Leary J. Prognosis communication in serious illness: perceptions of older patients, caregivers, and clinicians. J Am Geriatr Soc. 2003;51(10):1398–1403.
    1. Mack J.W., Cronin A., Keating N.L., et al. Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol. 2012;30(35):4387–4395.
    1. Wright A.A., Zhang B., Ray A., et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA. 2008;300(14):1665–1673.
    1. Weeks J.C., Cook E.F., O'Day S.J., et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA. 1998;279(21):1709–1714.
    1. Pronzato P., Bertelli G., Losardo P., et al. What do advanced cancer patients know of their disease? A report from Italy. Support Care Cancer. 1994;2(4):242–244.
    1. Jenkins V., Fallowfield L., Saul J. Information needs of patients with cancer: results from a large study in UK cancer centres. Br J Cancer. 2001;84(1):48–51.
    1. Arraras J.I., Greimel E., Chie W.C., et al. Cross-cultural differences in information disclosure evaluated through the EORTC questionnaires. Psychooncology. 2013;22(2):268–275.
    1. Fallowfield L.J., Jenkins V.A., Beveridge H.A. Truth may hurt but deceit hurts more: communication in palliative care. Palliat Med. 2002;16(4):297–303.
    1. Barnett M.M. Does it hurt to know the worst?–psychological morbidity, information preferences and understanding of prognosis in patients with advanced cancer. Psychooncology. 2006;15(1):44–55.
    1. Enzinger A.C., Zhang B., Schrag D., et al. Outcomes of prognostic disclosure: associations with prognostic understanding, distress, and relationship with physician among patients with advanced cancer. J Clin Oncol. 2015;33(32):3809–3816.
    1. Gattellari M., Voigt K.J., Butow P.N., et al. When the treatment goal is not cure: are cancer patients equipped to make informed decisions? J Clin Oncol. 2002;20(2):503–513.
    1. Hagerty R.G., Butow P.N., Ellis P.M., et al. Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis. J Clin Oncol. 2005;23(6):1278–1288.
    1. Smith T.J., Dow L.A., Virago E., et al. Giving honest information to patients with advanced cancer maintains hope. Oncology (Williston Park) 2010;24(6):521–525.
    1. Kiely B.E., McCaughan G., Christodoulou S., et al. Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Support Care Cancer. 2013;21(2):369–376.
    1. Stockler M.R., Tattersall M.H., Boyer M.J., et al. Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer. 2006;94(2):208–212.
    1. Kiely B.E., Martin A.J., Tattersall M.H., et al. The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates. J Clin Oncol. 2013;31(28):3565–3571.
    1. Fallowfield L.J., Catt S.L., May S.F., et al. Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits. Support Care Cancer. 2017;25(1):237–244.
    1. Hey S.P., Gyawali B., D'Andrea E., et al. A systematic review and meta-analysis of bevacizumab in first-line metastatic breast cancer: lessons for research and regulatory enterprises. J Natl Cancer Inst. 2020;112(4):335–342.
    1. Im S.A., Lu Y.S., Bardia A., et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–316.
    1. Slamon D.J., Neven P., Chia S., et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–524.
    1. Slamon D.J., Neven P., Chia S., et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472.
    1. Sledge G.W., Jr., Toi M., Neven P., et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, erbb2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2019;6(1):116–124.
    1. Sledge G.W., Jr., Toi M., Neven P., et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884.
    1. Tripathy D., Im S.A., Colleoni M., et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915.
    1. Tripathy D., Sohn J., Im S.-A., et al. Abstract GS2-05: first-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III MONALEESA-7 trial. Cancer Res. 2018;78(4 Supplement) GS2-05.
    1. Finn R.S., Martin M., Rugo H.S., et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
    1. Hortobagyi G.N., Stemmer S.M., Burris H.A., et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748.
    1. Rugo H.S., Finn R.S., Diéras V., et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719–729.
    1. di Leo A., Toi M., Campone M., et al. MONARCH 3: abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. Ann Oncol. 2017;28(suppl 5):v605–v649.
    1. Hortobagyi G.N., Stemmer S.M., Burris H.A., et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC) J Clin Oncol. 2017;35(15_suppl):1038.
    1. Cristofanilli M., Turner N.C., Bondarenko I., et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439.
    1. Goetz M.P., Toi M., Campone M., et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646.
    1. Harbeck N., Iyer S., Bhattacharyya H., et al. Impact of disease progression status on time to deterioration of patient reported health related quality of life in first line ER+ HER2- advanced/metastatic breast cancer patients in the PALOMA-2 study. Breast. 2017;36:S43.
    1. Johnston S., Martin M., Di Leo A., et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.
    1. Rugo H.S., Diéras V., Gelmon K.A., et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018;29(4):888–894.
    1. Verma S., O'Shaughnessy J., Burris H.A., et al. Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: results from MONALEESA-2. J Clin Oncol. 2017;35(15_suppl):1020.
    1. Harbeck N., Iyer S., Turner N., et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27(6):1047–1054.
    1. Kaufman P.A., Toi M., Neven P., et al. Health-related quality of life in MONARCH 2: abemaciclib plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. Oncologist. 2020;25(2):e243–e251.
    1. Turner N.C., Slamon D.J., Ro J., et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936.
    1. Verma S., Bartlett C.H., Schnell P., et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3) Oncologist. 2016;21(10):1165–1175.
    1. André F., Ciruelos E., Rubovszky G., et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940.
    1. Nunnery S.E., Mayer I.A. Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol. 2019;30(suppl 10):x21–x26.
    1. Rugo H.S., Lerebours F., Ciruelos E., et al. Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. J Clin Oncol. 2020;38(15_suppl):1006.
    1. Cardoso F., Senkus E., Costa A., et al. 4th ESO-ESMO International Consensus Guidelines for advanced breast cancer (ABC 4) Ann Oncol. 2018;29(8):1634–1657.
    1. Murthy R.K., Loi S., Okines A., et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.
    1. Lin N.U., Borges V., Anders C., et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610–2619.
    1. Modi S., Saura C., Yamashita T., et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621.
    1. Rugo H.S., Im S.-A., Wright G.L.S., et al. SOPHIA primary analysis: a phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx) J Clin Oncol. 2019;37(15_suppl):1000.
    1. Saura C., Oliveira M., Feng Y.-H., et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: findings from the multinational, randomized, phase III NALA trial. J Clin Oncol. 2019;37(15_suppl):1002.
    1. Pivot X., Manikhas A., Żurawski B., et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015;33(14):1564–1573.
    1. Schmid P., Adams S., Rugo H.S., et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121.
    1. Schmid P., Rugo H.S., Adams S., et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59.
    1. Cortes J., Cescon D.W., Rugo H.S., et al. KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J Clin Oncol. 2020;38(15_suppl):1000.
    1. Cortés J., Lipatov O., Im S., et al. KEYNOTE-119: phase 3 study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple-negative breast cancer (mTNBC) Ann Oncol. 2019;30(suppl 5):v851–v934.
    1. Bardia A., Mayer I.A., Vahdat L.T., et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741–751.
    1. Paluch-Shimon S., Cardoso F., Sessa C., et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016;27(suppl 5):v103–v110.
    1. Tung N.M., Robson M.E., Ventz S., et al. TBCRC 048: a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (olaparib expanded) J Clin Oncol. 2020;38(15_suppl):1002.
    1. Robson M.E., Tung N., Conte P., et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–566.
    1. Robson M., Im S.A., Senkus E., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533.
    1. Litton J.K., Rugo H.S., Ettl J., et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–763.
    1. Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib in germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from randomized phase 3 EMBRACA trial. AACR virtual annual meeting. 27-28 April 2020. Abstract CT071.
    1. Dieras V.C., Han H.S., Kaufman B., et al. Phase 3 study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer. Ann Oncol. 2019;30(suppl 5):v851–v934.
    1. Diaz L.A., Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–586.
    1. Alimirzaie S., Bagherzadeh M., Akbari M.R. Liquid biopsy in breast cancer: a comprehensive review. Clin Genet. 2019;95(6):643–660.
    1. Merker J.D., Oxnard G.R., Compton C., et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol. 2018;36(16):1631–1641.
    1. Condorelli R., Mosele F., Verret B., et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) Ann Oncol. 2019;30(3):365–373.
    1. Rugo H.S., Mayer I., Conte P., et al. Abstract CT142: prevalence of PIK3CA mutations in patients with hormone receptor-positive, human epidermal growth factor-2-negative advanced breast cancer from the SOLAR-1 trial. Cancer Res. 2019;79(13 Supplement):CT142.
    1. Juric D., Ciruelos E., Rubovszky G., et al. Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial. Cancer Res. 2019;79(4 Supplement) GS3-08.
    1. Juric D., Andre F., Singer C.F., et al. Abstract P4-10-04: clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: biomarker analysis from the SOLAR-1 study. Cancer Res. 2020;80(4 Supplement) P4-10-04.
    1. Fribbens C., O'Leary B., Kilburn L., et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34(25):2961–2968.
    1. Harbeck N., Penault-Llorca F., Cortes J., et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.
    1. Adam J., Le Stang N., Rouquette I., et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol. 2018;29(4):953–958.
    1. Rugo H.S., Loi S., Adams S., et al. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of IMpassion130. Ann Oncol. 2019;30(suppl 5):v851–v934.
    1. Wolff A.C., Hammond M.E.H., Allison K.H., et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol. 2018;36(20):2105–2122.
    1. Gloyeske N.C., Dabbs D.J., Bhargava R. Low ER+ breast cancer: is this a distinct group? Am J Clin Pathol. 2014;141(5):697–701.
    1. Deyarmin B., Kane J.L., Valente A.L., et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol. 2013;20(1):87–93.
    1. Iwamoto T., Booser D., Valero V., et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012;30(7):729–734.
    1. Balduzzi A., Bagnardi V., Rotmensz N., et al. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. Clin Breast Cancer. 2014;14(4):258–264.
    1. Yi M., Huo L., Koenig K.B., et al. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014;25(5):1004–1011.
    1. Chen T., Zhang N., Moran M.S., et al. Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysis. Clin Breast Cancer. 2018;18(1):1–8.
    1. Allison K.H., Hammond M.E.H., Dowsett M., et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update. J Clin Oncol. 2020;38(12):1346–1366.
    1. Coleman R., Hadji P., Body J-J., et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650–1663.
    1. Franzoi M.A., Hortobagyi G.N. Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol. 2019;135:85–94.
    1. Le Rhun E., Weller M., Brandsma D., et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017;28(suppl 4):iv84–iv99.
    1. Le Rhun E., Preusser M., van den Bent M., et al. How we treat patients with leptomeningeal metastases. ESMO Open. 2019;4(suppl 2):e000507.
    1. Roila F., Molassiotis A., Herrstedt J., et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119–v133.
    1. Cardoso F., Costa A., Norton L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1) Breast. 2012;21(3):242–252.
    1. Knaul F.M., Farmer P.E., Krakauer E.L., et al. Alleviating the access abyss in palliative care and pain relief—an imperative of universal health coverage: the Lancet Commission report. Lancet. 2018;391(10128):1391–1454.
    1. Fallon M., Giusti R., Aielli F., et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(suppl 4):iv166–iv191.
    1. Jones M.R., Viswanath O., Peck J., et al. A brief history of the opioid epidemic and strategies for pain medicine. Pain Ther. 2018;7(1):13–21.
    1. Page R., Blanchard E. Opioids and cancer pain: patients' needs and access challenges. J Oncol Pract. 2019;15(5):229–231.
    1. Cannabis and cannabinoids. Med Lett Drugs Ther. 2019;61(1585):179–182.
    1. Alves P., Amaral C., Teixeira N., et al. Cannabis sativa: much more beyond Δ(9)-tetrahydrocannabinol. Pharmacol Res. 2020;157:104822.
    1. Holmberg L., Iversen O.E., Rudenstam C.M., et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475–482.
    1. Fahlén M., Fornander T., Johansson H., et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 2013;49(1):52–59.
    1. Duijts S.F., van Beurden M., Oldenburg H.S., et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol. 2012;30(33):4124–4133.
    1. Mann E., Smith M.J., Hellier J., et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13(3):309–318.
    1. Stefanopoulou E., Grunfeld E.A. Mind-body interventions for vasomotor symptoms in healthy menopausal women and breast cancer survivors. A systematic review. J Psychosom Obstet Gynaecol. 2017;38(3):210–225.
    1. Lahart I.M., Metsios G.S., Nevill A.M., et al. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018;1(1):Cd011292.
    1. Hartman S.J., Nelson S.H., Myers E., et al. Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: the memory & motion study. Cancer. 2018;124(1):192–202.
    1. Ramaswami R., Villarreal M.D., Pitta D.M., et al. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2015;152(2):231–237.
    1. Johns C., Seav S.M., Dominick S.A., et al. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Res Treat. 2016;156(3):415–426.
    1. Shan D., Zou L., Liu X., et al. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;222(6):564–579.e12.
    1. Leon-Ferre R.A., Novotny P.J., Wolfe E.G., et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603) JNCI Cancer Spectr. 2020;4(1):pkz088.
    1. Chen W.Y., Giobbie-Hurder A., Gantman K., et al. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat. 2014;145(2):381–388.
    1. Innominato P.F., Lim A.S., Palesh O., et al. The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer. 2016;24(3):1097–1105.
    1. Mayer S., Iborra S., Grimm D., et al. Sexual activity and quality of life in patients after treatment for breast and ovarian cancer. Arch Gynecol Obstet. 2019;299(1):191–201.
    1. Stute P. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief? Arch Gynecol Obstet. 2013;288(6):1199–1201.
    1. Serati M., Bogani G., Di Dedda M.C., et al. A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive. Eur J Obstet Gynecol Reprod Biol. 2015;191:48–50.
    1. Origoni M., Cimmino C., Carminati G., et al. Postmenopausal vulvovaginal atrophy (VVA) is positively improved by topical hyaluronic acid application. A prospective, observational study. Eur Rev Med Pharmacol Sci. 2016;20(20):4190–4195.
    1. Donders G., Bellen G., Neven P., et al. Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. Eur J Clin Microbiol Infect Dis. 2015;34(10):2023–2028.
    1. Buchholz S., Mögele M., Lintermans A., et al. Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric. 2015;18(2):252–259.
    1. Mazzarello S., Hutton B., Ibrahim M.F.K., et al. Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat. 2015;152(1):1–8.
    1. Caruso S., Cianci S., Amore F.F., et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause. 2016;23(1):47–54.
    1. American College of Obstetricians and Gynecologists' Committee on Gynecologic Practice. Farrell R. ACOG Committee opinion no. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):e93–e96.
    1. Melisko M.E., Goldman M.E., Hwang J., et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017;3(3):313–319.
    1. Hersant B., SidAhmed-Mezi M., Belkacemi Y., et al. Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study. Menopause. 2018;25(10):1124–1130.
    1. Romero-Otero J., Lauterbach R., Aversa A., et al. Laser-based devices for female genitourinary indications: position statements from the European Society for Sexual Medicine (ESSM) J Sex Med. 2020;17(5):841–848.
    1. Bartula I., Sherman K.A. The Female Sexual Functioning Index (FSFI): evaluation of acceptability, reliability, and validity in women with breast cancer. Support Care Cancer. 2015;23(9):2633–2641.
    1. Mancha R.G., Muñoz M., de la Cruz-Merino L., et al. Development and validation of a sexual relations satisfaction scale in patients with breast cancer - “SEXSAT-Q”. Health Qual Life Outcomes. 2019;17(1):143.
    1. Reese J.B., Sorice K.A., Zimmaro L.A., et al. Communication about sexual health in breast cancer: what can we learn from patients' self-report and clinic dialogue? Patient Educ Couns. 2020;103(9):1821–1829.
    1. Dai Y., Cook O.Y., Yeganeh L., et al. Patient-reported barriers and facilitators to seeking and accessing support in gynecologic and breast cancer survivors with sexual problems: a systematic review of qualitative and quantitative studies. J Sex Med. 2020;17(7):1326–1358.
    1. Atkins L., Fallowfield L.J. Fallowfield's sexual activity questionnaire in women with without and at risk of cancer. Menopause Int. 2007;13(3):103–109.
    1. Gompel A., Ramirez I., Bitzer J. Contraception in cancer survivors - an expert review Part I. Breast and gynaecological cancers. Eur J Contracept Reprod Health Care. 2019;24(3):167–174.
    1. ABC Global Alliance ABC Global Charter 2018. ABC Global Alliance. Available at.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi